Technology Appraisal Committee Meeting (Committee D)

Minutes: Confirmed

Date and Time: Thursday 25 August 2016: 10.00 – 15.00

Venue: National Institute for Health and Care Excellence
Level 1A, City Tower
Piccadilly Plaza
Manchester
M1 4BT

Present: 1. Prof. Gary McVeigh, Chair Present for all notes
2. Dr Lindsay Smith, Vice Chair Present for all notes
3. Dr Andrew Black Present for all notes
4. Prof. David Bowen Present for all notes
5. Dr Matthew Bradley Present for all notes
6. Dr Ian Campbell Present for all notes
7. Mrs Susan Dutton Present for all notes
8. Mrs Gillian Ells Present for all notes
9. Prof. Paula Ghanegh Present for all notes
10. Dr Susan Griffin Present for all notes
11. Prof. John Henderson Present for all notes
12. Dr David Meads Present for all notes
13. Mr Malcolm Oswald Present for all notes
14. Prof. Oluwafemi Oyebode Present for all notes
15. Dr Paula Parvulescu Present for all notes

In attendance:

Nigel Armstrong ERG Representative, Kleijnen Systematic Reviews Ltd Present for notes 1 to 13

Dr Tim Benepal Clinical Expert, Consultant Medical Oncologist, nominated by the British Thoracic Oncology Group Present for notes 17 to 25

Miriam Brazzelli ERG Representative, Aberdeen HTA Group Present for notes 17 to 25

Karen Clayton Patient Expert, Macmillan Lung Cancer Nurse, nominated by the National Lung Cancer Forum for Nurses Present for notes 17 to 25

Sophie Cooper Technical Lead, National Institute for Health and Care Excellence Present for notes 1 to 16
<table>
<thead>
<tr>
<th>Name</th>
<th>Position</th>
<th>Present for notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joanne Ekeledo</td>
<td>Administrator, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Charles Gore</td>
<td>Patient Expert, nominated by the Hepatitis C Trust</td>
<td>Present for notes 1 to 13</td>
</tr>
<tr>
<td>Dr Syed Hyder Hussaini</td>
<td>Clinical Expert, Consultant Hepatologist, nominated by the British Society of Gastroenterology</td>
<td>Present for notes 1 to 13</td>
</tr>
<tr>
<td>Manuela Joore</td>
<td>ERG Representative, Kleijnen Systematic Reviews Ltd</td>
<td>Present for notes 1 to 13</td>
</tr>
<tr>
<td>Helen Knight</td>
<td>Associate Director, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Professor Carole Longson</td>
<td>Centre Director, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Kelvin Marshall</td>
<td>Patient Expert, nominated by Liver4Life</td>
<td>Present for notes 1 to 13</td>
</tr>
<tr>
<td>Fay McCracken</td>
<td>Technical Advisor, National Institute for Health and Care Excellence</td>
<td>Present for notes 17 to 29</td>
</tr>
<tr>
<td>Nicola McMeekin</td>
<td>ERG Representative, Aberdeen HTA Group</td>
<td>Present for notes 17 to 25</td>
</tr>
<tr>
<td>Kate Moore</td>
<td>Project Manager, National Institute for Health and Care Excellence</td>
<td>Present for all notes</td>
</tr>
<tr>
<td>Xavier Pouwels</td>
<td>ERG Representative, Kleijnen Systematic Reviews Ltd</td>
<td>Present for notes 1 to 13</td>
</tr>
<tr>
<td>Malcolm Qualie</td>
<td>NHS Commissioning expert, nominated by NHS England</td>
<td>Present for notes 1 to 13 and 17 to 25</td>
</tr>
<tr>
<td>Dr Stephen Ryder</td>
<td>Clinical Expert, Consultant Hepatologist, Nottingham University Hospitals, nominated by Gilead</td>
<td>Present for notes 1 to 13</td>
</tr>
<tr>
<td>Amaka Umeweni</td>
<td>Technical Advisor, National Institute for Health and Care Excellence</td>
<td>Present for notes 1 to 16</td>
</tr>
<tr>
<td>Stuart Wood</td>
<td>Technical Lead, National Institute for Health and Care Excellence</td>
<td>Present for notes 17 to 29</td>
</tr>
</tbody>
</table>
Olivia Wu  
ERG Representative,  
Aberdeen HTA Group  
Present for notes 17 to 25

Non-public observers:

Ann Greenwood  
Senior Medical Editor,  
National Institute for Health and Care Excellence  
Present for all notes

Caroline Hayto  
CDF Administrator,  
National Institute for Health and Care Excellence  
Present for all notes

Laura Norburn  
Public involvement programme, National Institute for Health and Care Excellence  
Present for all notes

Helen Powell  
Technical Lead, National Institute for Health and Care Excellence  
Present for all notes

Abi Senthinathan  
Technical Analyst, National Institute for Health and Care Excellence  
Present for all notes

Maroulla Whiteley  
Business Analyst - Resource Impact Assessment, National Institute for Health and Care Excellence  
Present for all notes

Notes

Welcome

1. The Chair welcomed all members of the Committee and other attendees present to the meeting. The Chair reviewed the agenda and timescales for the meeting, which included the appraisals of sofosbuvir-velpatasvir for treating chronic hepatitis C and pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.

2. The Chair informed the Committee of the non-public observers at this meeting: Ann Greenwood, Caroline Hayto, Laura Norburn, Helen Powell, Abi Senthinathan, and Marouella Whiteley,

3. Apologies were received from Dr Aomesh Bhatt, Ms Tracey Cole, Dr Ian Davidson, Professor Simon Dixon, Dr Alexander Dyker, Professor Carol Haigh, Dr Tim Kinnaird, Miss Sumithra Maheswaran and Dr Mohit Sharma.

Any other Business

4. None.
Appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C [ID921]

Part 1 – Open session

5. The Chair welcomed the invited experts: Nigel Armstrong, Charles Gore, Manuela Joore, Kelvin Marshall, Xavier Pouwels, Malcolm Qualie, Dr Syed Hyder Hussaini, and Dr Stephen Ryder to the meeting and they introduced themselves to the Committee.

6. The Chair welcomed company representatives from Gilead to the meeting.

7. The Chair asked all Committee members to declare any relevant interests

   7.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Andrew Black, Professor David Bowen, Dr Matthew Bradley, Dr Ian Campbell, Mrs Susan Dutton, Mrs Gillian Ells, Professor Paula Ghaneh, Professor John Henderson, Dr David Meads, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, and Dr Paula Parvulescu all declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C.

   7.2. Dr Susan Griffin declared a non-personal specific financial interest as she had previously been involved in a scoping project, commissioned through the Policy Research Programme, University of York, on behalf of NHS England, to look at treatment of hepatitis C in the UK. She was also a member of the Evidence Review Group for another hepatitis C appraisal.

   8.2.1 It was agreed that this declaration would not prevent Dr Susan Griffin from participating in this section of the meeting.

8. The Chair asked all NICE Staff to declare any relevant interests.

   8.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C.

9. The Chair asked all other invited guests to declare their relevant interests.

   9.1. Nigel Armstrong, Tim Benepal, Karen Clayton, Dr Syed Hyder Hussaini, Manuela Joore, Xavier Pouwels, and Malcolm Qualie declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of sofosbuvir-velpatasvir for treating chronic hepatitis C.
9.2. Charles Gore declared a personal non-specific financial interest as the Hepatitis C Trust had received funding from Gilead and comparator companies involved in this appraisal.
9.2.1. It was agreed that this declaration would not prevent Charles Gore from participating in this section of the meeting

9.3. Kelvin Marshall declared a personal non-specific financial interest Liver4Life had received educational grants from Gilead.
9.3.1. It was agreed that this declaration would not prevent Kelvin Marshall from participating in this section of the meeting

9.4. Dr Stephen Ryder declared a personal non-specific financial interest as he is an Advisory Board for Gilead.
9.4.1. It was agreed that this declaration would not prevent Dr Stephen Ryder from participating in this section of the meeting

10. The Chair introduced the lead team, Professor Carol Haigh, Professor John Henderson and Mr Malcolm Oswald, who gave presentations on the clinical effectiveness and cost effectiveness of sofosbuvir-velpatasvir for treating chronic hepatitis C.

11. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

12. The Chair explained that "representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest" (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)" and all public attendees left the meeting.

13. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

14. Discussion on confidential information continued. This information was supplied by the company.

15. The Committee continued to discuss the clinical and cost effectiveness of sofosbuvir-velpatasvir for treating chronic hepatitis C.

15.1. The committee decision was based on consensus.

16. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
Appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy [ID 840]

Part 1 – Open session

17. The Chair welcomed the invited experts: Dr Tim Benepal, Miriam Brazzelli, Karen Clayton, Nicola McMeekin, Malcolm Qualie and Olivia Wu to the meeting and they introduced themselves to the Committee.

18. The Chair welcomed company representatives from Merck Sharp & Dohme UK to the meeting.

19. The Chair asked all Committee members to declare any relevant interests

19.1. Professor Gary McVeigh, Dr Lindsay Smith, Dr Andrew Black, Professor David Bowen, Dr Matthew Bradley, Dr Ian Campbell, Mrs Susan Dutton, Mrs Gillian Ellis, Professor Paula Ghanem, Dr David Meads, Mr Malcolm Oswald, Professor Oluwafemi Oyebode, and Dr Paula Parvulescu declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.

19.2. Professor John Henderson declared a non-personal specific financial interest as his institution had received funding from Pfizer for unrelated research and a personal specific financial interest as he had received speaker fees from Novartis for an unrelated educational meeting.

19.2.1 It was agreed that this declaration would not prevent Professor John Henderson from participating in this section of the meeting.

19.3. Dr Susan Griffin declared a personal specific financial interest as she had taken part in an advisory board in November 2015 and was personally reimbursed by Novartis. The topic of the advisory board related to non-small cell lung cancer.

19.3.1 It was agreed that this declaration would not prevent Dr Susan Griffin from participating in this section of the meeting.

20. The Chair asked all NICE Staff to declare any relevant interests.

20.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.
21. The Chair asked all other invited guests to declare their relevant interests.

21.1. All declared that they knew of no personal specific financial interest, personal non-specific financial interest, non-personal specific financial interest, non-personal non-specific financial interest, personal specific family interest or personal non-specific family interest for any of the technologies to be considered as part of the appraisal of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.

22. The Chair introduced the key themes around the clinical effectiveness and cost effectiveness of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.

23. The Chair asked the company representatives whether they wished to comment on any matters of factual accuracy.

24. The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

25. The Chair then thanked the experts and company representatives for their attendance, participation and contribution to the appraisal and they left the meeting.

Part 2 – Closed session

26. Discussion on confidential information continued. This information was supplied by the company.

27. The Committee continued to discuss the clinical and cost effectiveness of pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after platinum-based chemotherapy.

27.1. The committee decision was based on consensus.

28. The Committee instructed the technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.

Date, time and venue of the next meeting

29. Wednesday 28 September 2016, 10.00 – 17.00 at National Institute for Health and Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester M1 4BT.